Wave takes a different tack from Sarepta in Duchenne
Wave will soon report key early-stage data with its exon-skipping DMD candidate suvodirsen but, unlike Sarepta, the group is starting its confirmatory trial before…
World Lung 2019 – Lilly celebrates a win with first Loxo asset
Impressive results in lung cancer with Eli Lilly’s Ret inhibitor set the stage for approval next year, but Blueprint is not far behind.
Upcoming events – Obseva's first fibroid foray and Newron's test in Retts
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
Ardelyx Amplified by first hyperphosphataemia success
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
ESC 2019 – Amarin hopes for guideline boost despite regulatory delay
Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?
ESC 2019 – Carmat is stout-hearted in the face of a challenging schedule
Carmat says its artificial heart is the best such device in existence. But time is short, and so is money.
Concert squares up to Pfizer in alopecia Jak bout
Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.
ESC 2019 – Medicines Company impresses with inclisiran
With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.
ESC 2019 – Astra’s latest Brilinta hopes bleed out on full Themis data
An increased risk of bleeding outweighs Brilinta’s benefits in a primary prevention population, but there might be a way forward in a patient subgroup.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.